Cedric Francois
CIK 1658080 · Chief Executive Officer · last filed 2026-05-14
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$0
Companies
1
Total Filings
70
Lifetime Open-Market Net
-$50.23M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Apellis Pharmaceuticals, Inc. (APLS) Delisted | Chief Executive Officer | 195,952 | $41.03 | $8.04M | -$50.23M | 70 | 2026-05-14 |
Recent Filings · Page 4 of 7
70 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-03-01 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Exer (M) | +100,000 | $376.0K | EDGAR |
| 2023-02-22 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Mixed | +12,306 | -$93.7K | EDGAR |
| 2023-02-14 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Tax (F) | −3,958 | -$202.7K | EDGAR |
| 2023-01-30 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Tax (F) | −2,879 | -$151.9K | EDGAR |
| 2023-01-24 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Tax (F) | −9,453 | -$492.0K | EDGAR |
| 2023-01-17 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Mixed | +83,447 | $0 | EDGAR |
| 2022-12-21 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Mixed | +9,188 | -$1.24M | EDGAR |
| 2022-02-14 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Tax (F) | −2,523 | -$118.9K | EDGAR |
| 2022-02-01 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Tax (F) | −2,024 | -$78.1K | EDGAR |
| 2022-01-25 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Grant (A) | +106,244 | $0 | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.